These changes in immune cells were associated with improved therapeutic efficacy in the R2LWT orthotopic murine HCC model, where systemic administration of MMR combined with antibodies that block PD-1/CTLA-4 resulted in tumor control that was superior to that resulting from either treatment alone. Here, PDCD1 is linked to neoplasm.